Literature DB >> 12839376

Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis.

Ajit Sood1, Vandana Midha, Neena Sood, Gurcharan Avasthi.   

Abstract

BACKGROUND: Azathioprine is useful as a steroid-sparing drug in patients with ulcerative colitis. Its role as monotherapy in the maintenance of disease remission has not been evaluated.
METHODS: In this prospective, randomized, open-label study, 25 patients with severe ulcerative colitis received either azathioprine (2.5 mg/Kg/day; Group A, n = 12) or sulfasalazine (6 g/day; Group B, n = 13). All patients received oral corticosteroids in a tapering dosage schedule initially. Treatment failure was defined as either disease relapse or drug withdrawal because of adverse effects.
RESULTS: Five of 12 patients in Group A and 8 of 13 patients in Group B had sustained remission during the stipulated study period of 18 months (p = ns). Two patients in Group A had to stop azathioprine because of adverse effects (bone marrow suppression and acute pancreatitis). In Group A, all patients who had treatment failure developed it in the first half of the study while in Group B treatment failure occurred in both halves.
CONCLUSIONS: The relapse rate of ulcerative colitis on maintenance therapy with azathioprine or sulfasalazine is comparable; there was a trend towards earlier treatment failure with azathioprine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12839376

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  14 in total

1.  Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease.

Authors:  Javier P Gisbert; María Chaparro; Fernando Gomollón
Journal:  World J Gastroenterol       Date:  2011-08-14       Impact factor: 5.742

2.  Long-Term Outcomes of Immunosuppression-Naïve Steroid Responders Following Hospitalization for Ulcerative Colitis.

Authors:  Amar Vedamurthy; Louise Xu; Jay Luther; Francis Colizzo; John J Garber; Hamed Khalili; Ashwin N Ananthakrishnan
Journal:  Dig Dis Sci       Date:  2018-06-27       Impact factor: 3.199

3.  Rebamipide enemas-new effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis.

Authors:  Mitsuki Miyata; Kunio Kasugai; Tetsuya Ishikawa; Shinichi Kakumu; Masafumi Onishi; Takeshi Mori
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

4.  Long term results of use of azathioprine in patients with ulcerative colitis in India.

Authors:  Ajit Sood; Vandana Midha; Neena Sood; Manu Bansal
Journal:  World J Gastroenterol       Date:  2006-12-07       Impact factor: 5.742

Review 5.  Medical therapy for ulcerative colitis: the state of the art and beyond.

Authors:  Andrew S Ross; Russell D Cohen
Journal:  Curr Gastroenterol Rep       Date:  2004-12

Review 6.  Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.

Authors:  Antje Timmer; Petrease H Patton; Nilesh Chande; John W D McDonald; John K MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2016-05-18

7.  Low-dose azathioprine is effective in maintaining remission in steroid-dependent ulcerative colitis: results from a territory-wide Chinese population-based IBD registry.

Authors:  Hai Yun Shi; Francis K L Chan; Wai Keung Leung; Michael K K Li; Chi Man Leung; Shun Fung Sze; Jessica Y L Ching; Fu Hang Lo; Steven W C Tsang; Edwin H S Shan; Lai Yee Mak; Belsy C Y Lam; Aric J Hui; Wai Hung Chow; Marc T L Wong; Ivan F N Hung; Yee Tak Hui; Yiu Kay Chan; Kam Hon Chan; Ching Kong Loo; Carmen K M Ng; Wai Cheung Lao; Marcus Harbord; Justin C Y Wu; Joseph J Y Sung; Siew C Ng
Journal:  Therap Adv Gastroenterol       Date:  2016-04-19       Impact factor: 4.409

8.  AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis.

Authors:  Joseph D Feuerstein; Kim L Isaacs; Yecheskel Schneider; Shazia Mehmood Siddique; Yngve Falck-Ytter; Siddharth Singh
Journal:  Gastroenterology       Date:  2020-01-13       Impact factor: 22.682

9.  AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis.

Authors:  Siddharth Singh; Jessica R Allegretti; Shazia Mehmood Siddique; Jonathan P Terdiman
Journal:  Gastroenterology       Date:  2020-01-13       Impact factor: 22.682

10.  Combination Therapy with Sulfasalazine and Valproic Acid Promotes Human Glioblastoma Cell Death Through Imbalance of the Intracellular Oxidative Response.

Authors:  Carlos Gustavo Garcia; Suzana Assad Kahn; Luiz Henrique Medeiros Geraldo; Igor Romano; Ivan Domith; Deborah Christinne Lima E Silva; Fernando Dos Santos Assunção; Marcos José Ferreira; Camila Cabral Portugal; Jorge Marcondes de Souza; Luciana Ferreira Romão; Annibal Duarte Pereira Netto; Flávia Regina Souza Lima; Marcelo Cossenza
Journal:  Mol Neurobiol       Date:  2018-01-19       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.